{"id":"high-bup-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds with high affinity to mu-opioid receptors in the central nervous system, producing analgesia and reducing cravings in opioid use disorder. At higher doses, it achieves greater receptor saturation and clinical efficacy while maintaining a ceiling effect on respiratory depression compared to full mu-opioid agonists. This Phase 3 trial likely evaluates optimized dosing regimens for improved treatment outcomes.","oneSentence":"High-dose buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and opioid dependence treatment through sustained receptor occupancy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:16.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"},{"name":"Chronic pain management"}]},"trialDetails":[{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT05589181","phase":"PHASE3","title":"High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-04-06","conditions":"Opioid Use Disorder","enrollment":140},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT00315341","phase":"PHASE4","title":"Starting Treatment With Agonist Replacement Therapies (START)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-04","conditions":"Opiate-related Disorders","enrollment":1269},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Subutex"],"phase":"phase_3","status":"active","brandName":"High Bup Dose","genericName":"High Bup Dose","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and opioid dependence treatment through sustained receptor occupancy. Used for Opioid use disorder, Chronic pain management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}